BrightSpring's Growth Came From Both Pricing and Expansion

BrightSpring Health Services raised its 2026 outlook after a quarter in which both pharmacy economics and home-health expansion lifted results. Revenue increased 26.4% to $4.21 billion, while adjusted EBITDA rose 42.0% to $228 million. The shares gained about 12% after the report.

The figures cover continuing operations because BrightSpring divested its Community Living business in March. Net income from continuing operations was $101 million, up from $38 million a year earlier, and gross profit increased 32.3% to $519 million. Leverage fell to 1.79 times from 2.15 times at the end of June, giving the company more financial flexibility after an acquisition-heavy period.

Pharmacy Solutions remained the largest business. Segment revenue rose 26% to $3.73 billion, even though prescription volume increased only 1.5%. Revenue per prescription climbed 24% to $340.86, and gross profit per prescription rose 27% to $28.86. The widening profit contribution per prescription explains why consolidated gross profit grew faster than revenue.

That performance also needs a qualification. Drug prices, reimbursement rates and product mix can move pharmacy revenue per prescription even when prescription volume changes little. CFO Jennifer Phipps said in September that 2026 represented the peak year for the effect of Medicare drug-price negotiations and that the 2027 impact should be roughly half as large, according to the source report. Investors should still watch whether gross profit per prescription holds as negotiated prices and reimbursement rules evolve.

Provider Services revenue rose 31% to $481 million. Home-health average daily census jumped 58% to 47,256, helped by 107 branches BrightSpring acquired from Amedisys and LHC Group. Those businesses were divested as part of UnitedHealth Group's Amedisys transaction. BrightSpring now expects the branches to contribute about $35 million of adjusted EBITDA in 2026.

The company increased full-year revenue guidance to $15.90 billion to $16.13 billion, representing growth of 23.2% to 24.9%. It expects Pharmacy Segment revenue of $14.00 billion to $14.20 billion and Provider Segment revenue of $1.90 billion to $1.93 billion. Adjusted EBITDA guidance rose to $850 million to $860 million, or growth of 37.6% to 39.3%. The outlook excludes the Community Living business and any future acquisitions that have not yet closed.

The quarter shows two different growth engines. Pharmacy results benefited from higher revenue and gross profit per prescription, while the provider business added scale through acquired branches and a larger patient census. Both can support growth, but they carry different risks: pharmacy margins depend on prices and reimbursement, while provider growth depends on integrating branches without weakening care quality or labor economics.

BrightSpring's next test is whether those gains persist after the acquisition comparison becomes less favorable. Stable gross profit per prescription, lower leverage and continued census growth would show that the raised guidance rests on durable operating improvements rather than a single strong quarter.